136 related articles for article (PubMed ID: 7804831)
1. Retention of basic fibroblast growth factor immunoreactivity in dopaminergic neurons of the substantia nigra during normal aging in humans contrasts with loss in Parkinson's disease.
Tooyama I; McGeer EG; Kawamata T; Kimura H; McGeer PL
Brain Res; 1994 Sep; 656(1):165-8. PubMed ID: 7804831
[TBL] [Abstract][Full Text] [Related]
2. Loss of basic fibroblast growth factor in substantia nigra neurons in Parkinson's disease.
Tooyama I; Kawamata T; Walker D; Yamada T; Hanai K; Kimura H; Iwane M; Igarashi K; McGeer EG; McGeer PL
Neurology; 1993 Feb; 43(2):372-6. PubMed ID: 8437705
[TBL] [Abstract][Full Text] [Related]
3. Immunohistochemical analyses of fibroblast growth factor receptor-1 in the human substantia nigra. Comparison between normal and Parkinson's disease cases.
Walker DG; Terai K; Matsuo A; Beach TG; McGeer EG; McGeer PL
Brain Res; 1998 Jun; 794(2):181-7. PubMed ID: 9622624
[TBL] [Abstract][Full Text] [Related]
4. Loss of non-phosphorylated neurofilament immunoreactivity, with preservation of tyrosine hydroxylase, in surviving substantia nigra neurons in Parkinson's disease.
Gai WP; Vickers JC; Blumbergs PC; Blessing WW
J Neurol Neurosurg Psychiatry; 1994 Sep; 57(9):1039-46. PubMed ID: 7916375
[TBL] [Abstract][Full Text] [Related]
5. Neurofilament mRNA is reduced in Parkinson's disease substantia nigra pars compacta neurons.
Hill WD; Arai M; Cohen JA; Trojanowski JQ
J Comp Neurol; 1993 Mar; 329(3):328-36. PubMed ID: 8459049
[TBL] [Abstract][Full Text] [Related]
6. The substantia nigra of the human brain. II. Patterns of loss of dopamine-containing neurons in Parkinson's disease.
Damier P; Hirsch EC; Agid Y; Graybiel AM
Brain; 1999 Aug; 122 ( Pt 8)():1437-48. PubMed ID: 10430830
[TBL] [Abstract][Full Text] [Related]
7. Age-associated increases of alpha-synuclein in monkeys and humans are associated with nigrostriatal dopamine depletion: Is this the target for Parkinson's disease?
Chu Y; Kordower JH
Neurobiol Dis; 2007 Jan; 25(1):134-49. PubMed ID: 17055279
[TBL] [Abstract][Full Text] [Related]
8. Alpha-synuclein redistributes to neuromelanin lipid in the substantia nigra early in Parkinson's disease.
Halliday GM; Ophof A; Broe M; Jensen PH; Kettle E; Fedorow H; Cartwright MI; Griffiths FM; Shepherd CE; Double KL
Brain; 2005 Nov; 128(Pt 11):2654-64. PubMed ID: 16000336
[TBL] [Abstract][Full Text] [Related]
9. Dopamine transporter messenger RNA in Parkinson's disease and control substantia nigra neurons.
Uhl GR; Walther D; Mash D; Faucheux B; Javoy-Agid F
Ann Neurol; 1994 Apr; 35(4):494-8. PubMed ID: 8154880
[TBL] [Abstract][Full Text] [Related]
10. Age-related changes in basic fibroblast growth factor-immunoreactive cells of rat substantia nigra.
Lolova IS; Lolov SR
Mech Ageing Dev; 1995 Aug; 82(2-3):73-89. PubMed ID: 8538246
[TBL] [Abstract][Full Text] [Related]
11. The physiological and pharmacological role of basic fibroblast growth factor in the dopaminergic nigrostriatal system.
Grothe C; Timmer M
Brain Res Rev; 2007 Apr; 54(1):80-91. PubMed ID: 17229467
[TBL] [Abstract][Full Text] [Related]
12. Detrimental deletions: mitochondria, aging and Parkinson's disease.
Biskup S; Moore DJ
Bioessays; 2006 Oct; 28(10):963-7. PubMed ID: 16998822
[TBL] [Abstract][Full Text] [Related]
13. Relative sparing in Parkinson's disease of substantia nigra dopamine neurons containing calbindin-D28K.
Yamada T; McGeer PL; Baimbridge KG; McGeer EG
Brain Res; 1990 Sep; 526(2):303-7. PubMed ID: 2257487
[TBL] [Abstract][Full Text] [Related]
14. Imaging of dopamine transporters with [123I]FP-CIT SPECT does not suggest a significant effect of age on the symptomatic threshold of disease in Parkinson's disease.
Booij J; Bergmans P; Winogrodzka A; Speelman JD; Wolters EC
Synapse; 2001 Feb; 39(2):101-8. PubMed ID: 11180497
[TBL] [Abstract][Full Text] [Related]
15. Nurr1 in Parkinson's disease and related disorders.
Chu Y; Le W; Kompoliti K; Jankovic J; Mufson EJ; Kordower JH
J Comp Neurol; 2006 Jan; 494(3):495-514. PubMed ID: 16320253
[TBL] [Abstract][Full Text] [Related]
16. An altered histaminergic innervation of the substantia nigra in Parkinson's disease.
Anichtchik OV; Rinne JO; Kalimo H; Panula P
Exp Neurol; 2000 May; 163(1):20-30. PubMed ID: 10785440
[TBL] [Abstract][Full Text] [Related]
17. Regional distribution of monoamine vesicular uptake sites in the mesencephalon of control subjects and patients with Parkinson's disease: a postmortem study using tritiated tetrabenazine.
Thibaut F; Faucheux BA; Marquez J; Villares J; Menard JF; Agid Y; Hirsch EC
Brain Res; 1995 Sep; 692(1-2):233-43. PubMed ID: 8548309
[TBL] [Abstract][Full Text] [Related]
18. Age-related decreases in Nurr1 immunoreactivity in the human substantia nigra.
Chu Y; Kompoliti K; Cochran EJ; Mufson EJ; Kordower JH
J Comp Neurol; 2002 Aug; 450(3):203-14. PubMed ID: 12209851
[TBL] [Abstract][Full Text] [Related]
19. In vivo imaging of neuromelanin in Parkinson's disease using 18F-AV-1451 PET.
Hansen AK; Knudsen K; Lillethorup TP; Landau AM; Parbo P; Fedorova T; Audrain H; Bender D; Østergaard K; Brooks DJ; Borghammer P
Brain; 2016 Jul; 139(Pt 7):2039-49. PubMed ID: 27190023
[TBL] [Abstract][Full Text] [Related]
20. Immunocytochemical analysis of tumor necrosis factor and its receptors in Parkinson's disease.
Boka G; Anglade P; Wallach D; Javoy-Agid F; Agid Y; Hirsch EC
Neurosci Lett; 1994 May; 172(1-2):151-4. PubMed ID: 8084523
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
